## (19) World Intellectual Property Organization International Bureau



## 

## (43) International Publication Date 6 May 2005 (06.05.2005)

**PCT** 

## (10) International Publication Number WO 2005/039640 A1

(51) International Patent Classification7: A61K 45/06, A61P 1/04

(21) International Application Number:

PCT/US2004/027776

(22) International Filing Date: 25 August 2004 (25.08.2004)

(25) Filling Language:

English

(26) Publication Language:

**English** 

(30) Priority Data: 60/508,416

3 October 2003 (03.10.2003)

(71) Applicant (for all designated States except US): AL-LERGAN INC. [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): OLEJNIK, Orest [US/US]; 5 Addington Place, Coto De Caza, CA 92679 (US). BAKHIT, Peter, G. [US/US]; 21661 Brookhurst #144, Huntington Beach, CA 92646 (US). GRAHAM. Richard [US/US]; 5066 Balsawood, Irvine, CA 92612

(US). WELTY, Devin, Franklin [US/US]; 37 Tessera Drive, Poothill Ranch, CA 92610 (US). TANG-LIU, Diane, D. [US/US]; 2615 Blackthorn Street, Newport Beach, CA 92660 (US).

(74) Agents: JOHNSON, Brent, A. et al.; c/o Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EB, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),



inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.